Replication data for: Cystatin C proteoforms in chronic kidney diseasedoi:10.18710/NUNHDFDataverseNO2021-04-301Dierkes, Jutta, 2021, "Replication data for: Cystatin C proteoforms in chronic kidney disease", https://doi.org/10.18710/NUNHDF, DataverseNO, V1Replication data for: Cystatin C proteoforms in chronic kidney diseasedoi:10.18710/NUNHDFDierkes, JuttaDahl, HeleneSandnes, KristinaWelland, Natasha L.Andresen, IselinMeyer, KlausLysne, VegardMarti, Hans-PeterDierkes, JuttaUniversity of BergenUniversity of Bergen, and Haukeland University HospitalR studioDataverseNOUniversity of BergenDierkes, JuttaDierkes, Jutta2021-04-24Medicine, Health and Life SciencesCystatin CKidney DiseasesProteoformchronic kidney disesaseSupplementary dataset to 'Cystatin C proteoforms in chronic kidney disease'
This is a cross-sectional study on cystatin C proteoforms in patients with chronic kidney disease. The study was done at the University of Bergen and Haukeland University Hospital, Bergen, Norway.
In total, 157 patients with various degrees of chronic kidney disease were included, and proteoforms of cystatin C were measured with MALDI-TOF. This dataset contains supplementary information.<p>
<p> ABSTRACT:
<p> Cystatin C, a cysteine protease inhibitor, is used as a biomarker of renal function. It offers several advantages compared to creatinine, and formulas for the estimation of the glomerular filtration rate based on cystatin C have been developed. Recently, several proteoforms of cystatin C have been discovered, including an intact protein with a hydroxylated proline at the N-terminus, and N-terminal truncated forms. There is little knowledge about the biological significance of these proteoforms.
<p> Methods: Cross-sectional study of patients with different stages of chronic renal disease (pre-dialysis n=53; hemodialysis n=51, renal transplant n=53). Measurement of cystatin C proteoforms by MALDI-TOF MS, assessment of medicine prescription using the first two levels of the Anatomical Therapeutic chemical system from patients’ records.
<p>Results: Patients receiving hemodialysis had the highest cystatin C concentrations, followed by pre-dialysis patients and patients with a renal transplant. In all groups, the most common proteoforms were native cystatin C and CysC 3Pro-OH while the truncated forms made up 28%. The distribution of the different proteoforms was largely independent of renal function and total cystatin C. However, the use of corticosteroids (ATC-L02) and immunosuppressants (ATC-H04) considerably impacted the distribution of proteoforms.
<p>Conclusion: The different proteoforms of cystatin C increased proportionally with total cystatin C in patients with chronic kidney disease. Prescription of corticosteroids and immunosuppressants had a significant effect on the distribution of proteoforms. The biological significance of these proteoforms remains to be determined.clinical dataGao, Jie; Meyer, Klaus; Borucki, Karin; Ueland, Per Magne. Multiplex Immuno-MALDI-TOF MS for Targeted Quantification of Protein Biomarkers and Their Proteoforms Related to Inflammation and Renal Dysfunction. Anal. Chem. 2018, 90, 5, 3366–3373. https://doi.org/10.1021/acs.analchem.7b04975Dierkes, J., Dahl, H., Lervaag Welland, N. et al. High rates of central obesity and sarcopenia in CKD irrespective of renal replacement therapy – an observational cross-sectional study. BMC Nephrol 19, 259 (2018). https://doi.org/10.1186/s12882-018-1055-600_README.txtREADME file for dataset 'Cystatin C proteoforms in chronic kidney disease*text/plainDahl_cysC_protforms_suppl_fig1.tifsupplementary figure 1. Proportion of proteoforms of CysC with estimated GFR (eGFR) based on creatinine, cystatin C or both, and with total cystatin C in patients with pre-dialysis chronic kidney disease (CKD 3-5), patients receiving hemodialysis (HD) and in renal transplant recipients (KTX). image/tiffPrescribedMedications.txtSupplementary Table 2: Prescribed medications in the study population according to treatment group (CKD 3-5 chronic kidney disease stage 3-5, HD patients receiving hemodialysis, KTX renal transplant recipients)
ATC anatomical therapeutic chemical classificationtext/plainStudyPopulation_characteristics_CKD.txtCharacteristics of study population by CKD stage
text/plain